NR1I2

Nuclear receptor subfamily 1 group I member 2 · O75469 · NR1I2 on Sugi Atlas →

444,022 patent compounds predicted against NR1I2, 309,705 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Cefotaxime (SCHEMBL15410)	1.00	6/20
Cefotaxime (SCHEMBL15411)	1.00	6/20
Ceftriaxone (SCHEMBL23355)	1.00	6/20
Ceftriaxone (SCHEMBL23356)	1.00	6/20
Cefpodoxime (SCHEMBL27072)	1.00	6/20
Ceftriaxone (SCHEMBL23354)	0.80	6/20
Cefpodoxime Proxetil (SCHEMBL27071)	0.75	6/20
Cefixime (SCHEMBL24945)	0.64	5/20
Cefixime (SCHEMBL24946)	0.64	5/20
Miconazole (SCHEMBL2866)	1.00	4/20
(R)-Miconazole (SCHEMBL2867)	1.00	4/20
Cephalothin (SCHEMBL2990)	1.00	4/20
Cefoxitin (SCHEMBL15971)	1.00	4/20
Miconazole (SCHEMBL3366)	0.98	4/20
(R)-Miconazole (SCHEMBL3367)	0.98	4/20
Miconazole (SCHEMBL15799)	0.84	4/20
(R)-Miconazole (SCHEMBL15800)	0.84	4/20
Enilconazole (SCHEMBL22498)	0.71	4/20
SCHEMBL5331	0.54	4/20
Aztreonam (SCHEMBL26423)	0.52	4/20

Clinical trials — most relevant to NR1I2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills	PHASE4	COMPLETED
Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation	PHASE3	COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	PHASE3	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer	PHASE2	UNKNOWN
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)	PHASE1	COMPLETED
Drug Interaction and Food Effect Study of CS0159	PHASE1	COMPLETED
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT	nan	COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Sexual Hormones and Haemostasis: Observations for Women Health	nan	UNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	nan	NOT_YET_RECRUITING
Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling	nan	COMPLETED
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone	nan	COMPLETED
Metabolic Investigation, Physical Performance, Physical Training At Different Times of the Day in Obese Women	nan	ACTIVE_NOT_RECRUITING
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN
HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients	nan	COMPLETED
LXR and Oocyte Meiosis Resumption	nan	UNKNOWN
Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NR1I2 binder may also engage these)

Protein	Name	Similarity
O54915	—	1.000	O54915 →
Q9R1A7	—	1.000	Q9R1A7 →
Q8SQ01	—	1.000	Q8SQ01 →
A3RGC1	—	0.997	A3RGC1 →
Q1L673	—	0.996	Q1L673 →
NR1H3	Oxysterols receptor LXR-alpha	0.996	landscape →
P49701	—	0.996	P49701 →
Q62685	—	0.996	Q62685 →
Q28037	—	0.995	Q28037 →
F1QLY4	—	0.995	F1QLY4 →
VDR	Vitamin D3 receptor	0.995	landscape →
Q0ZAQ8	—	0.995	Q0ZAQ8 →
Q5E9B6	—	0.994	Q5E9B6 →
Q9TU15	—	0.994	Q9TU15 →
THRA	Thyroid hormone receptor alpha	0.994	landscape →
RORC	Nuclear receptor ROR-gamma	0.994	landscape →
Q9QXZ7	—	0.994	Q9QXZ7 →
P18119	—	0.994	P18119 →
P51448	—	0.993	P51448 →
P48281	—	0.993	P48281 →
P13053	—	0.993	P13053 →
Q9XSB5	—	0.993	Q9XSB5 →
Q28570	—	0.993	Q28570 →
Q9PTU5	—	0.993	Q9PTU5 →
THRB	Thyroid hormone receptor beta	0.993	landscape →
O42392	—	0.992	O42392 →
P37242	—	0.992	P37242 →
P18113	—	0.992	P18113 →
O97716	—	0.992	O97716 →
Q5RAP4	—	0.992	Q5RAP4 →